Role of volumetric parameters obtained from 68 Ga-PSMA PET/CT and 18F-FDG PET/CT in predicting overall survival in patients with mCRPC receiving taxane therapy

Basit Öğe Kaydı
dc.contributor.authorGuzel, Yunus
dc.contributor.authorKomek, Halil
dc.contributor.authorCan, Canan
dc.contributor.authorKaplan, Ihsan
dc.contributor.authorAkdeniz, Nadiye
dc.contributor.authorKepenek, Ferat
dc.contributor.authorGundogan, Cihan
dc.date.accessioned2024-04-24T16:02:44Z
dc.date.available2024-04-24T16:02:44Z
dc.date.issued2023
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjectiveThe aim of this study was to determine the prognostic role of volumetric parameters and Pro-PET scores obtained from (68) Ga-prostate-specific membrane antigen (PSMA) PET/CT and F-18-FDG PET/CT in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving taxane therapy.Materials and methodsThe study included 71 patients who underwent simultaneous PSMA and F-18-FDG PET/CT imaging between January 2019 and January 2022, had a Pro-PET score of 3-5 and had received taxane therapy after imaging. F-18-FDG tumor volume (TV-F) and PSMA tumor volume (TV-P) values of the lesions and total lesion glycolysis (TL-G) and total lesion PSMA (TL-P) values of the lesions were calculated on both imaging studies and the effects of these parameters on overall survival (OS) were investigated.ResultsThe median age of the patients included herein was 71 years (56-89) and the median prostate-specific antigen (PSA) level was 16.4 (0.01-1852 ng/dL). According to the Kaplan-Meier survival analysis, TTV-P >= 78.5, TTL-P >= 278.8, TTV-F >= 94.98, TTL-G >= 458.3, TTV-P + F >= 195.45, TTL-G + P >= 855.78, lymph node (L)TV-FDG >= 3.4, LFDG-SUVmax >= 3.2, LFDG-SUVmean >= 2.25, LFDG-SUVpeak >= 2.55, and bone (B)TV-F >= 51.15 values were found to be prognostic factors in predicting short OS. Multivariate Cox regression analysis showed that a Vscore >= 3 (95% confidence interval [CI]: 7.069-98.251, p < 0.001) and TTL-G + P >= 855.78 (95% CI: 4.878-1037.860, p = 0.006) were found to be independent prognostic factors in predicting short OS.ConclusionVolumetric parameters and Pro-PET scores obtained from (68) Ga-PSMA PET/CT and F-18-FDG PET/CT imaging have been shown to have an impact on OS in patients with mCRPC receiving taxane therapy.en_US
dc.identifier.doi10.1007/s12149-023-01854-9
dc.identifier.endpage527en_US
dc.identifier.issn0914-7187
dc.identifier.issn1864-6433
dc.identifier.issue9en_US
dc.identifier.pmid37332068
dc.identifier.startpage517en_US
dc.identifier.urihttps://doi.org/10.1007/s12149-023-01854-9
dc.identifier.urihttps://hdl.handle.net/11468/14894
dc.identifier.volume37en_US
dc.identifier.wosWOS:001009991700001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofAnnals of Nuclear Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectF-18-Fdgen_US
dc.subject(68) Ga-Psmaen_US
dc.subjectMtven_US
dc.subjectTlgen_US
dc.subjectPro-Pet Scoreen_US
dc.titleRole of volumetric parameters obtained from 68 Ga-PSMA PET/CT and 18F-FDG PET/CT in predicting overall survival in patients with mCRPC receiving taxane therapyen_US
dc.titleRole of volumetric parameters obtained from 68 Ga-PSMA PET/CT and 18F-FDG PET/CT in predicting overall survival in patients with mCRPC receiving taxane therapy
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu